All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Catch up with our live social media coverage of aggressive B-NHL from the European Hematology Association (EHA) 2024 Hybrid Congress.
June 13—16
To update you on the exciting content presented at the European Hematology Association (EHA) 2024 Hybrid Congress, we have collated our social media coverage. Catch up with our live social media relating to Aggressive B-NHL, here.
CONGRESS #EHA2024 | Jeremy Abramson reports 3-yr follow-up data of the TRANSFORM trial of liso-cel in pts with R/R LBCL. mFU= 33.9 mo, ORR=87%, CR=74%, 36 mo PFS=50.9%, 36 mo OS=62.8% - superior to SoC. Safety was consistent with interim and primary analyses. No grade 4/5 CRS… pic.twitter.com/4voVaYLr7o
— Lymphoma Hub (@lymphomahub) June 16, 2024
CONGRESS #EHA2024 | Jeremy Abramson reports 3-yr follow-up data of the TRANSFORM trial of liso-cel in pts with R/R LBCL. mFU= 33.9 mo, ORR=87%, CR=74%, 36 mo PFS=50.9%, 36 mo OS=62.8% - superior to SoC. Safety was consistent with interim and primary analyses. No grade 4/5 CRS… pic.twitter.com/4voVaYLr7o
— Lymphoma Hub (@lymphomahub) June 16, 2024
CONGRESS #EHA2024 | Poster | Mingci Cai at Shanghai institute of hematology reports phase 2 study of tazemetostat plus amdizalisib in pts with R/R lymphomas. N=21. Azemetostat plus amdizalisib shown promising efficacy and safety in R/R lymphoma, particularly in PTCL and DLBCL,… pic.twitter.com/rInM2KkFCb
— Lymphoma Hub (@lymphomahub) June 15, 2024
CONGRESS | #EHA2024 | David Lavie, Hadassah Medical Center presents first data of SC administration of epcoritamab + POLA-R-CHP for the treatment of first-line DLBCL.
— Lymphoma Hub (@lymphomahub) June 15, 2024
ORR 100%, CR 88.6%, median duration of CR not reached, Grade 3/4 TEAE 76%, neutropenia 65% (all GR 3/4), CRS… pic.twitter.com/hCHbwz6m8o
CONGRESS | #EHA2024 | Sirpa Leppä @helsinkiuni shares data on biomarker-adapted treatment in high-risk LBCL. All versus biol high-risk patients 5-year OS 89% and 88%, PFS 83% and 77%, DA-EPOCH-R regimens may improve outcomes in biol-HR patients.#lymsm pic.twitter.com/1HPxEbDLf7
— Lymphoma Hub (@lymphomahub) June 15, 2024
CONGRESS | #EHA2024 | Marcel Nijland presents the final analysis from the HOVON 151 clinical trial of atezolizumab consolidation in high-risk DLBCL. 2-year DFS 87.9%, Grade 3/4 immune-related AEs 4.5%, infections were the most common toxicity, with nearly 50% COVID-19,… pic.twitter.com/vgQkXiy6du
— Lymphoma Hub (@lymphomahub) June 15, 2024
CONGRESS | #EHA2024
— Lymphoma Hub (@lymphomahub) June 15, 2024
Marie José Kersten @UvA_Amsterdam @amsterdamumc presents findings from the ongoing phase I/II ATALANTA-1 trial of GLPG5101, showing the feasibility of decentralized CAR T-cell manufacturing in 33 patients with R/R NHL, with a short vein-to-vein time and no… pic.twitter.com/ihWzxHrD0S
CONGRESS | #EHA2024
— Lymphoma Hub (@lymphomahub) June 15, 2024
Jean Galtier @CHUBordeaux reports on 55 patients with R/R PMBCL treated with axi-cel in the French DESCAR-T registry (CARTHYM study).
▪️ Strong efficacy seen (ORR=91%, CR=80%)
▪️ At median follow-up of 23 months, estimated 2-yr PFS=68.7%; median PFS not… pic.twitter.com/A5J1B4rz24
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox